JADE CURY MARTINS ASFORA LINS
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
- Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model(2015) SCARISBRICK, Julia J.; PRINCE, H. Miles; VERMEER, Maarten H.; QUAGLINO, Pietro; HORWITZ, Steven; PORCU, Pierluigi; STADLER, Rudolf; WOOD, Gary S.; BEYLOT-BARRY, Marie; PHAM-LEDARD, Anne; FOSS, Francine; GIRARDI, Michael; BAGOT, Martine; MICHEL, Laurence; BATTISTELLA, Maxime; GUITART, Joan; KUZEL, Timothy M.; MARTINEZ-ESCALA, Maria Estela; ESTRACH, Teresa; PAPADAVID, Evangelia; ANTONIOU, Christina; RIGOPOULOS, Dimitis; NIKOLAOU, Vassilki; SUGAYA, Makoto; MIYAGAKI, Tomomitsu; GNIADECKI, Robert; SANCHES, Jose Antonio; CURY-MARTINS, Jade; MIYASHIRO, Denis; SERVITJE, Octavio; MUNIESA, Cristina; BERTI, Emilio; ONIDA, Francesco; CORTI, Laura; HODAK, Emilia; AMITAY-LAISH, Iris; ORTIZ-ROMERO, Pablo L.; RODRIGUEZ-PERALTO, Jose L.; KNOBLER, Robert; PORKERT, Stefanie; BAUER, Wolfgang; PIMPINELLI, Nicola; GRANDI, Vieri; COWAN, Richard; ROOK, Alain; KIM, Ellen; PILERI, Alessandro; PATRIZI, Annalisa; PUJOL, Ramon M.; WONG, Henry; TYLER, Kelly; STRANZENBACH, Rene; QUERFELD, Christiane; FAVA, Paolo; MAULE, Milena; WILLEMZE, Rein; EVISON, Felicity; MORRIS, Stephen; TWIGGER, Robert; TALPUR, Rakhshandra; KIM, Jinah; OGNIBENE, Grant; LI, Shufeng; TAVALLAEE, Mahkam; HOPPE, Richard T.; DUVIC, Madeleine; WHITTAKER, Sean J.; KIM, Youn H.Purpose Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sezary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers. Patients and Methods Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS). Results Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and 52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients diagnosed with stage III disease had slightly improved survival compared with patients with stage IIB, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year survival rates: low risk (68%), intermediate risk (44%), and high risk (28%). Conclusion To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic index, may be useful to stratify advanced-stage patients. (C) 2015 by American Society of Clinical Oncology
- Progression of mycosis fungoides after treatment with dupilumab: A case report(2020) MIYASHIRO, Denis; VIVARELLI, Ana Gabriela; GONCALVES, Fernanda; CURY-MARTINS, Jade; SANCHES, Jose Antonio
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital(2022) CEGLIO, William Queiroz Guimaraes Wiegandt; REBEIS, Marina Mattos; SANTANA, Marcela Ferreira; MIYASHIRO, Denis; CURY-MARTINS, Jade; SANCHES, Jose AntonioBackground: Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen. Objective: To evaluate the most common adverse events, as well as the drugs associated with their appearance and the consequences for cancer treatment. Methods: A retrospective study was carried out through the analysis of patients treated at the Clinical Dermatology Unit of a public oncologic hospital. Results: A total of 138 patients with 200 adverse events were evaluated. The most commonly identified adverse events were nail and periungual changes (20%), papulopustular eruptions (13%), acneiform eruptions (12%), hand-foot syndrome (6.5%), hand-foot skin reaction (6%), and xerosis (6%). The most frequently associated antineoplastic treatment groups were classical chemotherapy (46.2%), target therapy (32.3%), and other non-antineoplastic drugs used in neoplasia protocols (16.5%). Of the total number of patients, 17.4% had their treatment suspended or changed due to a dermatological adverse event. Study limitations: Retrospective study and analysis of patients who were referred for specialized dermatological examination only, not allowing the assessment of the actual incidence of adverse events. Conclusion: A wide variety of dermatological manifestations are secondary to antineoplastic treatment with several different drugs resulting, not rarely, in the interruption or modification of therapeutic regimens. (C) 2021 Sociedade Brasileira de Dermatologia.
- Granulomatous slack skin: A series of cases(2018) MIOTTO, Isadora; MIYASHIRO, Denis; MARTINS, Jade; SANCHES, Jose Antonio
- Quality of life in patients with mycosis fungoides and Sezary syndrome is significantly worse in female patients, Sezary syndrome and those with more extensive skin involvement(2018) MOLLOY, Kevin; EVISON, Felicity; PENG, Chenjing; GUENOVA, Emmanuella; COWAN, Richard; BUSSCHOTS, Annemie; WOEI-A-JIN, Sherida H.; BERVOETS, An; HAUBEN, Esther; BEYLOT-BARRY, Marie; JONAK, Constanze; KNOBLER, Robert; POKERT, Stefanie; PAPADAVID, Evangelina; VAKEVA, Liisa; MATIN, Rubeta; BATES, Andrew; ESTRACH, Teresa; PRINCE, Miles; TWIGGER, Robert; BERTI, Emilio; VIOLETTI, Silvia Alberti; BAYNE, Mike; MCKAY, Pam; WACHSMUCH, Rachel; AKILOV, Oleg; MCCANN, Susan; DAMASCO, Fabiana; SANCHES, Jose Antonio; MIYASHIRO, Denis; CURY-MARTINS, Jade; TURNER, Deborah; WOBSER, Marion; BENSTEAD, Kim; YOO, Jinah; SCARISBRICK, Julia
- Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil(2019) FERREIRA, Cristiane Rubia; ZHAO, Shuchun; SANCHES, Jose Antonio; MIYASHIRO, Denis; CURY-MARTINS, Jade; AZEVEDO, Raymundo Soares; ZERBINI, Maria C. N.; NATKUNAM, Yasodha; GRATZINGER, DitaBackground Primary cutaneous CD30+ lymphoproliferative disorders (pc-CD30-LPD) are a group of clonal T cell lymphoproliferative disorders that despite very similar tumor histology follow different and characteristic clinical courses, suggesting a homeostatic role of the tumor microenvironment. Little is known about tumor microenvironment and there is almost no literature about PD-L1 expression in pc-CD30-LPD. Methods This retrospective study presents a fully clinicopathologically characterized series of pc-CD30-LPDs from an academic medical center in Brazil, including 8 lymphomatoid papulomatosis (LyP), 9 primary cutaneous anaplastic large cell lymphoma (pcALCL) and 4 borderline lesions. All the cases were scored for FOXP3+ regulatory T-cells (Treg) and CD8+ cytotoxic tumor infiltrating lymphocytes (TIL) densities, as well as PD-L1 expression in tumor cells and tissue associated macrophages. The CD8+/FOXP3+ ratio was also evaluated. Results Among the 21 cases of pc-CD30-LPD, PD-L1 expression is frequent in both tumor cells and tissue associated macrophages in pc-CD30-LPD across categories, suggesting that the PD-L1 axis may be a common feature of pc-CD30-LPDs. While reactive T cell infiltrates vary widely from case to case, a common feature across pc-CD30-LPDs is higher density of CD8 than FOXP3 + T cells. The distribution of T cells within the lesions however differed between LyP and pcALCL: we found that LyP lesions tend to be permeated by CD8+ and FOXP3+ T cells, whereas pcALCL tend to be surrounded by a rim of CD8+ TIL and FOXP3+ Tregs with relatively lower density infiltrates in the center of the lesion. Conclusions LyP has a trend to have denser immune cells throughout the lesion, with higher FOXP3+ Treg and CD8+ TIL in the center than the edge comparing with pcALCL. PD-L1+ is frequent in tumor cells and tissue associated macrophages in pc-CD30-LPD. The differential distribution of CD8+ and FOXP3+ TILs in LyP as compared to pcALCL could provide a clue to the relapsing/remitting course of LyP as compared to the less frequent spontaneous regression of pcALCL.
- Survival rates and hematological parameters of Sezary syndrome treated with chlorambucil or interferon: An acceptable alternative when photopheresis is not available?(2018) CURY-MARTINS, Jade; MIYASHIRO, Denis; PEREIRA, Juliana; ABDO, Andre; SANCHES, Jose Antonio
- Mycosis fungoides and Sezary syndrome: focus on the current treatment scenario(2021) SANCHES, Jose Antonio; CURY-MARTINS, Jade; ABREU, Rodrigo Martins; MIYASHIRO, Denis; PEREIRA, JulianaCutaneous T-cell lymphomas are a heterogeneous group of lymphoproliferative disorders, characterized by infiltration of the skin by mature malignant T cells. Mycosis fungoides is the most common form of cutaneous T-cell lymphoma, accounting for more than 60% of cases. Mycosis fungoides in the early-stage is generally an indolent disease, progressing slowly from some patches or plaques to more widespread skin involvement. However, 20% to 25% of patients progress to advanced stages, with the development of skin tumors, extracutaneous spread and poor prognosis. Treatment modalities can be divided into two groups: skin-directed therapies and systemic therapies. Therapies targeting the skin include topical agents, phototherapy and radiotherapy. Systemic therapies include biological response modifiers, immunotherapies and chemotherapeutic agents. For early-stage mycosis fungoides, skin-directed therapies are preferred, to control the disease, improve symptoms and quality of life. When refractory or in advanced-stage disease, systemic treatment is necessary. In this article, the authors present a compilation of current treatment options for mycosis fungoides and Sezary syndrome. (C) 2021 Sociedade Brasileira de Dermatologia.
- A unique case of a lymphoproliferative disorder affecting the skin and uterine cervix on a male transgender(2024) CURY-MARTINS, Jade; GIANNOTTI, Marcelo A.; MIYASHIRO, Denis; PEREIRA, Juliana; SANCHES, Jose Antonio